Masahito Kotaka

ORCID

Publication Activity (10 Years)

Years Active: 2020-2022
Publications (10 Years): 5

Top Venues

Cancer chemotherapy and pharmacology

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

PloS one

International journal of clinical oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Takayuki Yoshino, Eiji Oki, Toshihiro Misumi, Masahito Kotaka, Dai Manaka, Tetsuya Eto, Junichi Hasegawa, Akinori Takagane, Masato Nakamura, Takeshi Kato, Yoshinori Munemoto, Fumitaka Nakamura, Hiroyuki Bando, Hiroki Taniguchi, Yasuhiro Sakamoto, Manabu Shiozawa, Masayasu Nishi, Tetsuya Horiuchi, Hisakazu Yamagishi, Junichi Sakamoto, Tsunekazu Mizushima, Atsushi Ohtsu, Masaki Mori
Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (29) (2022)
Masahito Kotaka, Shigeyoshi Iwamoto, Hironaga Satake, Daisuke Sakai, Toshihiro Kudo, Mutsumi Fukunaga, Ken Konishi, Yoshihito Ide, Taro Ikumoto, Akihito Tsuji, Yasushi Sano, Takeshi Kato, Naotoshi Sugimoto, Taroh Satoh, Akiyoshi Kanazawa, Takayasu Kurata, Takeharu Yamanaka, Naohiro Tomita
Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study). International journal of clinical oncology 25 (8) (2020)
Misato Ogata, Masahito Kotaka, Takatsugu Ogata, Yukimasa Hatachi, Hisateru Yasui, Takeshi Kato, Akihito Tsuji, Hironaga Satake
Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan. PloS one 15 (6) (2020)
Masahito Kotaka, Yoji Saito, Takeshi Kato, Hironaga Satake, Akitaka Makiyama, Yasushi Tsuji, Katsunori Shinozaki, Toshiyoshi Fujiwara, Tsunekazu Mizushima, Yasushi Harihara, Naoki Nagata, Naoto Kurihara, Masahiko Ando, Genichi Kusakawa, Takumi Sakai, Yugo Uchida, Mikihiro Takamoto, Saki Kimoto, Ichinosuke Hyodo
A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy. Cancer chemotherapy and pharmacology 86 (5) (2020)
Masahito Kotaka, Yoji Saito, Takeshi Kato, Hironaga Satake, Akitaka Makiyama, Yasushi Tsuji, Katsunori Shinozaki, Toshiyoshi Fujiwara, Tsunekazu Mizushima, Yasushi Harihara, Naoki Nagata, Naoto Kurihara, Masahiko Ando, Genichi Kusakawa, Takumi Sakai, Yugo Uchida, Mikihiro Takamoto, Saki Kimoto, Ichinosuke Hyodo
Correction to: A placebo‑controlled, double‑blind, randomized study of recombinant thrombomodulin (ART‑123) to prevent oxaliplatin‑induced peripheral neuropathy. Cancer chemotherapy and pharmacology (2020)

Masahito Kotaka.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Masahito Kotaka